IMGCAP(1)]
NEW YORK | Mon Jan 23, 2012 9:42am EST (Reuters) – When your health insurance provider denies an experimental treatment or a high-cost drug, how much are you willing to pay for the care you believe you need?
More From Employee Benefit News
With GLP-1s raising costs, employers are finding new ways to reduce spending
As healthcare expenses approach double-digit increases, employers are looking for savings in waste, care delivery, and plan administration before cutting benefits.
The expanding role of AI in open enrollment, part 1
As artificial intelligence continues to move into the mainstream, opportunities abound for eliminating confusion, personalizing content and improving outcomes.
What the 2027 ACA marketplace proposal means for employers
While the legislation's future is still unclear, there are many important things for leaders to know.
Employers face a new GLP-1 question: Are the drugs worth it?
As GLP-1 spending climbs, employers are asking whether the drugs deliver enough value. Better data could help them measure the payoff more accurately.
GLP-1s push health plan costs to 15-year high
Rising use of the weight-loss drug is fueling the fastest health plan cost growth in a decade and a half, forcing employers to rethink coverage strategies and cost management.
